Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

Lung Cancer

Volumn 41, Issue SUPPL. 1, 2003, Pages 89-96

  Mack, Philip C ^a   Davies, Angela M ^a   Lara, Primo N ^a   Gumerlock, Paul H ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lung cancer; Proteasome inhibitor; PS 341

Indexed keywords

BORTEZOMIB; CARBOPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P53;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; BACKACHE; CANCER CHEMOTHERAPY; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; COUGHING; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DRUG TOXICITY; DYSPNEA; EDEMA; FATIGUE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; ILEUM DISEASE; LEUKOPENIA; LIMB PAIN; LUNG CARCINOMA; MOLECULAR DYNAMICS; NAUSEA; PELVIS PAIN SYNDROME; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; PRURITUS; RASH; SKIN DISEASE; THROMBOCYTOPENIA; URINARY DYSFUNCTION; VOMITING;

EID: 0038012270     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00149-1     Document Type: Conference Paper

References (51)

1. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr. Opin. Cell. Biol. 9:1997;788-799.
2. Liu C.W., Corboy M.J., DeMartino G.N., Thomas P.J. Endoproteolytic activity of the proteasome. Science. 299:2003;408-411.
3. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 7:2002;9-16.
4. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622.
5. Frankel A., Man S., Elliott P., Adams J., Kerbel R.S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 6:2000;3719-3728.
6. Adams J., Palombella V.J., Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs. 18:2000;109-121.
7. Gandara D.R., Lara P.N., Lau D.H., Mack P., Gumerlock P.H. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 3:(34 Suppl.):2001;S75-80.
8. Sclafani R.A., Schauer I.E. Cell cycle control and cancer: lessons from lung cancer. J. Invest. Dermatol. Symp. Proc. 1:1996;123-127.
9. Harbour J.W., Lai S.L., Whang-Peng J., Gazdar A.F., Minna J.D., Kaye F.J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 241:1988;353-357.
10. Hayashi H., Ogawa N., Ishiwa N., et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer. 34:2001;59-65.
11. Xue Q., Sano T., Kashiwabara K., Oyama T., Nakajima T. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung. Jpn. J. Cancer Res. 92:2001;285-292.
12. Blagosklonny M.V., Wu G.S., Omura S., el-Deiry W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 227:1996;564-569.
13. An W.G., Hwang S.G., Trepel J.B., Blagosklonny M.V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia. 14:2000;1276-1283.
14. Catzavelos C., Tsao M.S., DeBoer G., Bhattacharya N., Shepherd F.A., Slingerland J.M. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 59:1999;684-688.
15. Esposito V., Baldi A., De Luca A., et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385.
16. Kubbutat M.H., Vousden K.H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17:1997;460-468.
17. Blagosklonny M.V. P53: an ubiquitous target of anticancer drugs. Int. J. Cancer. 98:2002;161-166.
18. Cusack J.C. Jr, Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:2001;3535-3540.
19. Chen F., Chang D., Goh M., Klibanov S.A., Ljungman M. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell. Growth Differ. 11:2000;239-246.
20. Lopes U.G., Erhardt P., Yao R., Cooper G.M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272:1997;12893-12896.
21. Herrmann J.L., Briones F. Jr, Brisbay S., Logothetis C.J., McDonnell T.J. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene. 17:1998;2889-2899.
22. Henkel T., Machleidt T., Alkalay I., Kronke M., Ben-Neriah Y., Baeuerle P.A. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature. 365:1993;182-185.
23. Ghosh S., Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature. 344:1990;678-682.
24. Wang C.Y., Cusack J.C. Jr, Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5:1999;412-417.
25. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7:2001;1419-1428.
26. Kim J.Y., Lee S., Hwangbo B., et al. NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis. Biochem. Biophys. Res. Commun. 273:2000;140-146.
27. Jones DR, Broad RM, Madrid LV, Baldwin AS, Jr, Mayo MW. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis, Ann Thorac Surg 2000;70:930-36; discussion 936-37.
28. Russo S.M., Tepper J.E., Baldwin A.S. Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;183-193.
29. Sohur U.S., Dixit M.N., Chen C.L., Byrom M.W., Kerr L.A. Rel/NF-kappaB represses bcl-2 transcription in pro-B lymphocytes. Gene Expr. 8:1999;219-229.
30. Kaiser U., Schilli M., Haag U., et al. Expression of bcl-2 - protein in small cell lung cancer. Lung Cancer. 15:1996;31-40.
31. Borner M.M., Brousset P., Pfanner-Meyer B., et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br. J. Cancer. 79:1999;952-958.
32. Reeve J.G., Xiong J., Morgan J., Bleehen N.M. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer. 73:1996;1193-1200.
33. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA. 97:2000;3850-3855.
34. Bold R.J., Virudachalam S., McConkey D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100:2001;11-17.
35. Bold R.J., Chandra J., McConkey D.J. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann. Surg. Oncol. 6:1999;279-285.
36. Ravi R., Bedi G.C., Engstrom L.W., et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell. Biol. 3:2001;409-416.
37. Weinstein J.N., Myers T.G., O'Connor P.M., et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
38. Teicher B.A., Ara G., Herbst R., Palombella V.J., Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5:1999;2638-2645.
39. Pervan M., Pajonk F., Sun J.R., Withers H.R., McBride W.H. Molecular pathways that modify tumor radiation response. Am. J. Clin. Oncol. 24:2001;481-485.
40. Gumerlock P.H., Kawaguchi T., Moisan L.P., et al. Mechanisms of enhanced cytotoxicity from docetaxel plus PS-341 combination in non-small cell lung carcinoma (NSCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;1214.
41. Garfield D. Proteasome inhibitor PS-341 and docetaxel: sequence of administration may be crucial. The Lancet. 2:2001;714.
42. Investigators Brochure MP, Inc., November 2000.
43. Papandreou CDD, Millikan RE, Tu S-M, et al. Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (Pts) with advanced malignancies, Proc Am Soc Clin Oncol 2001; Abstr #340.
44. Lightcap E.S., McCormack T.A., Pien C.S., Chau V., Adams J., Elliott P.J. Proteasome inhibition measurements: clinical application. Clin. Chem. 46:2000;673-683.
45. Logothetis CJ, Yang H, Daliani D, et al. Dose dependent inhibition of 20S proteasome results in serum Il-6 and PSA decline in patients (PTS) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341, Proc Am Soc Clin Oncol 2001; Abstr# 740.
46. Aghajanian C, Soignet S, Dizon D, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies, Proc Am Soc Clin Oncol 2001; Abstr# 338.
47. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20:2002;4420-4427.
48. Hamilton AL, Eder JP, Pavlick AC, et al. PS-341: phase i study of a novel proteasome inhibitor with pharmacodynamic endpoints, Proc Am Soc Clin Oncol 2001; Abstr# 336.
49. Erlichman C, Adjei AA, Thomas JP, et al. A phase I trial of the proteasome inhibitor PS-341 in patients with advanced cancer, Proc Am Soc Clin Oncol 2001; Abstr# 337.
50. Ryan DP, Eder JP, Winkelmann J, et al. Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors, Proc Am Soc Clin Oncol 2002; Abstr# 379.
51. O. Kashala, Personal Communication, Millennium Pharmaceuticals.